Novartis Boosts Sandoz Generic Business With Acquisition Of Eon, Hexal
This article was originally published in The Pink Sheet Daily
Executive Summary
Addition of U.S., German companies will make Sandoz the global leader in generic sales, with combined 2004 pro forma revenues of $5.1 bil., Novartis says. Acquisition will enable Sandoz to become the "preferred partner" for "authorized" generic deals and to play a leading role in development of follow-on biologics.
You may also be interested in...
Wealthy Families Play A Growing Role in European Biotech Financing
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.
Wealthy Families Play A Growing Role in European Biotech Financing
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.
Vasella Knocks AstraZeneca Acquisition Rumor
Novartis CEO Daniel Vasella dismissed rumors that the firm is considering acquisition of rival drug maker AstraZeneca July 17